The short-term promise and long-term problem

If you have been told microfracture is your best option for a painful cartilage defect, it is worth asking a follow-up question: best option over what timeframe? The procedure is still carried out at considerable scale — around 78,000 times a year in the United States alone — and for very small, contained defects under 2 cm² it can deliver meaningful early pain relief. The problem is what happens next.

Microfracture works by puncturing the underlying bone to draw in the body's own repair cells. Those cells lay down fibrocartilage — a type of scar tissue composed mainly of type I collagen — rather than the type II collagen-rich hyaline cartilage that lines healthy joint surfaces. Hyaline cartilage is stiffer, smoother, and far better suited to absorbing the repetitive loads a knee endures. Fibrocartilage simply does not hold up in the same way.

Kreuz et al. documented this in a landmark 2006 study — now cited nearly a thousand times — showing that clinical results after microfracture begin to deteriorate beyond 36 months. Subsequent systematic reviews have refined that picture further: regression commonly starts at 18–24 months, becomes clinically significant in the three-to-five-year window, and, for many patients, function drifts back towards preoperative levels by a decade as the repair tissue wears away.

The question the evidence now poses is not whether microfracture can relieve symptoms — it often can, in the short term — but whether that relief lasts long enough, and whether the repair it creates is adequate for the size and demands of the defect being treated.

Why fibrocartilage is not the same as the cartilage you started with

That distinction in tissue type has direct mechanical consequences. Think of it as the difference between a canvas patch and the original woven fabric: the patch may cover the gap, but it does not share the same structure, tensile strength, or durability as what it replaced. Fibrocartilage lacks the organised, load-bearing matrix of native articular cartilage, which means it deforms more readily under the forces a knee routinely absorbs — walking, stair-climbing, and sport all exert loads several times body weight across the joint surface. The repair tissue may look reassuringly dense on early post-operative MRI scans, but imaging appearance and mechanical behaviour diverge over time as the fibrocartilage gradually breaks down under repetitive stress.

The procedure itself adds a further complication beyond the quality of the repair tissue. Repeatedly perforating the subchondral bone plate — the dense layer of bone immediately beneath the cartilage — can trigger adverse structural changes. Intralesional osteophytes (bony growths within the defect) and subchondral cysts are recognised sequelae, and both alter the contour and integrity of the joint surface. This matters not only for the patient's immediate symptoms but for what comes next: a compromised subchondral plate makes it substantially harder to achieve secure fixation or adequate cell integration if a more advanced procedure — such as MACI or osteochondral allograft transplantation — is needed later. Put simply, the biological downside of microfracture is not confined to the repair tissue it creates; it can narrow the surgical options available at revision.

MACI: the cell-based option with the strongest trial evidence

MACI — Matrix-Induced Autologous Chondrocyte Implantation — takes a fundamentally different approach: rather than recruiting whatever repair cells the bone marrow can supply, it starts with the patient's own chondrocytes, cultures them in a laboratory, and seeds them onto a type I/III collagen membrane before implantation. The membrane holds the cells in position across the defect and provides the structural scaffold for hyaline-like cartilage to form — a tissue closer in composition to what was originally lost than the fibrocartilage microfracture produces.

The clinical evidence for MACI in moderate-to-large defects is the most robust of any restorative technique currently available. The SUMMIT trial (Brittberg 2018), a prospective randomised controlled trial, enrolled patients with symptomatic knee defects of 3 cm² or larger and followed them for five years. MACI produced statistically and clinically significant improvements in KOOS pain and function scores at both two- and five-year timepoints compared with microfracture. The responder-rate difference is telling: the proportion of patients who reached a meaningful, sustained recovery threshold — defined as at least a 10-point improvement in both pain and function — was significantly higher with MACI (P=0.016). By 2025, Schneider et al. describe MACI as the 'gold standard' for moderate-to-large focal lesions in a multi-technique comparative study.

Two trade-offs warrant honest acknowledgement. The procedure is two-stage — an initial biopsy to harvest cartilage cells, followed weeks later by implantation — which means two separate recovery periods and higher overall cost than single-stage options such as AMIC. Long-term randomised data beyond five years for MACI specifically also remains limited; the mid-term results are encouraging, but decade-long RCT evidence equivalent to what now exists for AMIC has not yet been published.

AMIC: single-stage repair with a decade of follow-up data

The data gap just mentioned is precisely where AMIC stands apart. A 2024 randomised controlled trial by Volz (PMC11291581, n=47), with patients followed for a full decade, provides the longest-horizon head-to-head comparison currently available. Both AMIC groups — one membrane fixed by suture, one by glue — improved steadily over the first two years, as did the microfracture group. After that point, trajectories diverged sharply: microfracture scores showed progressive, significant deterioration while both AMIC groups remained stable throughout the remaining eight years.

What AMIC adds mechanically is straightforward: a bilayer collagen membrane (Chondro-Gide®) is placed over the microfracture site to contain and protect the bone-marrow superclot. The membrane holds the MSC-rich clot in position rather than allowing it to disperse, providing a scaffold that guides chondrogenesis toward more durable repair tissue. There is no cell-culture step and no second operation — the entire procedure is completed in a single stage.

The 2024 systematic review by Ong et al. corroborates the trial findings across a broader evidence base: AMIC consistently yields higher IKDC and Lysholm scores than isolated microfracture, along with lower revision rates. For defects in the 2–4 cm² range where a one-stage approach is clinically appropriate, this body of evidence is now substantial.

One qualification applies. The evidence reviewed here concentrates on the knee; the NHS HRA REPAIR trial is actively investigating AMIC in acetabular (hip) defects, and outcomes in that joint remain less certain pending its results.

OCA: restoring bone and cartilage in larger or complex defects

For patients with defects larger than 2–4 cm², those where the underlying bone has also been damaged, or those who have already undergone a previous cartilage procedure that has since broken down, osteochondral allograft (OCA) transplantation is the reconstruction option of choice.

Where MACI and AMIC address the cartilage layer alone, OCA transplants donor tissue that includes both hyaline cartilage and its intact subchondral bone support — making it the only technique in common use that addresses both components simultaneously in a single operation. The graft comes from a matched donor rather than the patient's own body, which removes the donor-site harvesting problem associated with autograft procedures, though it introduces the practical consideration of matching and sourcing appropriate allograft tissue; this logistical step can affect scheduling and should be discussed openly at consultation.

Graft survival rates of 78–81% at five to ten years are consistently reported across cohort studies — a meaningful durability figure for a patient population that often has limited alternatives and for whom joint replacement would otherwise be the next conversation.

For large focal lesions specifically, the Matthews 2022 cohort study (n=148, mean follow-up 6.7 years) found no significant difference in KOOS JR or IKDC scores between OCA and ACI — both techniques performed equivalently well at this defect size. The same data confirm that both fall well above microfracture outcomes, reinforcing defect size as one of the clearest guides to technique selection.

Choosing the right technique for your defect size and circumstances

Defect size is the most reliable starting point for technique selection. For lesions under 2 cm² in structurally sound subchondral bone, AMIC offers a single-stage step up from plain microfracture with substantially more durable outcomes; isolated microfracture may still be appropriate where cost or single-stage simplicity is the overriding constraint. Between 2 and 4 cm², the choice between AMIC and MACI often comes down to whether a two-stage pathway is feasible: MACI's RCT evidence base is stronger, but AMIC's decade of follow-up data makes it a well-supported alternative when a single operation is the priority. Above 4 cm², or where bone loss is present, OCA is the most appropriate reconstruction — and as the Matthews 2022 cohort confirms, ACI and MACI perform equivalently at this scale too.

One factor that defect-size algorithms tend to underweight is the history of prior marrow stimulation. A failed microfracture leaves structural changes in the subchondral bone that narrow what revision surgery can achieve; the relevant clinical question is not only what technique fits the lesion, but what the subchondral bed will support.

Limb alignment, activity level, and individual anatomy all bear on the final decision alongside imaging. Rather than a fixed algorithm, technique selection benefits from objective biomechanical assessment and detailed imaging review — the kind of evaluation available at MSK Doctors clinics in Sleaford and Grantham, where appointments can be arranged without a GP referral at mskdoctors.com.